Modafinil for daytime somnolence in Parkinson's disease: Double blind, placebo controlled parallel trial

William G. Ondo, R. Fayle, Farah Atassi, J. Jankovic

Research output: Contribution to journalArticle

198 Scopus citations

Abstract

Background: Excessive daytime somnolence (EDS) commonly complicates Parkinson's disease (PD). The aetiology of EDS is probably multifactorial but is probably exacerbated by dopaminergic medications. Modafinil is a wake-promoting agent approved for use in narcolepsy, but it is often used to treat a variety of somnolent conditions. Method: A double blind, placebo controlled parallel design trial was conducted to assess the efficacy of modafinil (200-400 mg/day) for the treatment of EDS in PD. The primary efficacy measure was the Epworth Sleepiness (ES) scale score. Secondary efficacy points included the Unified Parkinson's Disease Rating Scale (UPDRS), the Fatigue Severity Scale, the Hamilton Depression Scale, and the multiple sleep latency test (MSLT). Results: Of a total of 40 subjects (29 men, mean (SD) age 64.8 (11.3) years), randomised to modafinil or placebo, 37 completed the study. Modafinil failed to significantly improve ES scores compared with placebo (2.7 v 1.5 points improvement, respectively, p = 0.28). MSLT failed to improve with modafinil relative to placebo (-0.16 v -0.70, respectively, p = 0.14). UPDRS, global impressions, Fatigue Severity Scale, and Hamilton Depression Scale scores were unchanged. Adverse events were minimal. Conclusion: Modafinil failed to significantly improve EDS in PD compared with placebo. The drug did not alter motor symptoms in PD and was well tolerated.

Original languageEnglish (US)
Pages (from-to)1636-1639
Number of pages4
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume76
Issue number12
DOIs
StatePublished - Dec 2005

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Modafinil for daytime somnolence in Parkinson's disease: Double blind, placebo controlled parallel trial'. Together they form a unique fingerprint.

Cite this